BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Jan 18, 2016
Clinical News

Cerenis HDL: Phase III started

Cerenis began the double-blind, placebo-controlled, international Phase III TANGO trial to evaluate 8 mg/kg IV CER-001 for 48 weeks in about 30 patients. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France   Product: Cerenis HDL ( CER-001 )  ...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest PPARδ agonists could help treat HD. PPARδ activity and mitochondrial membrane potential were lower in primary cortical neurons from a mutant huntingtin (HTT) mouse model of HD...
BC Week In Review | Aug 3, 2015
Clinical News

Cerenis HDL: Phase II data

An investigator-initiated, open-label, Dutch Phase II trial in 8 patients with atherosclerotic carotid artery disease showed that single doses of 3 mg/kg CER-001 labeled with Zirconium-89 led to a 14% increase in uptake of CER-001...
BioCentury | May 11, 2015
Finance

Debuting Biocartis

The €100 million ($107.8 million) IPO by Biocartis Group N.V. (Euronext:BCART) isn't settling the question of whether European biotechs should look at home or to the U.S. for capital, but the molecular diagnostics company's strong...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
BC Week In Review | Mar 30, 2015
Financial News

Cerenis Therapeutics S.A completes IPO

Cerenis Therapeutics S.A . (Euronext:CEREN), Labege, France   Business: Cardiovascular, Endocrine/Metabolic   Date completed: 2015-03-26   Type: IPO   Raised: EUR53.4 million ($57.7 million)   Shares: 4.2 million   Price: EUR12.70   Shares after offering: 17.8...
BC Extra | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
Items per page:
1 - 10 of 57
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Jan 18, 2016
Clinical News

Cerenis HDL: Phase III started

Cerenis began the double-blind, placebo-controlled, international Phase III TANGO trial to evaluate 8 mg/kg IV CER-001 for 48 weeks in about 30 patients. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France   Product: Cerenis HDL ( CER-001 )  ...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest PPARδ agonists could help treat HD. PPARδ activity and mitochondrial membrane potential were lower in primary cortical neurons from a mutant huntingtin (HTT) mouse model of HD...
BC Week In Review | Aug 3, 2015
Clinical News

Cerenis HDL: Phase II data

An investigator-initiated, open-label, Dutch Phase II trial in 8 patients with atherosclerotic carotid artery disease showed that single doses of 3 mg/kg CER-001 labeled with Zirconium-89 led to a 14% increase in uptake of CER-001...
BioCentury | May 11, 2015
Finance

Debuting Biocartis

The €100 million ($107.8 million) IPO by Biocartis Group N.V. (Euronext:BCART) isn't settling the question of whether European biotechs should look at home or to the U.S. for capital, but the molecular diagnostics company's strong...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
BC Week In Review | Mar 30, 2015
Financial News

Cerenis Therapeutics S.A completes IPO

Cerenis Therapeutics S.A . (Euronext:CEREN), Labege, France   Business: Cardiovascular, Endocrine/Metabolic   Date completed: 2015-03-26   Type: IPO   Raised: EUR53.4 million ($57.7 million)   Shares: 4.2 million   Price: EUR12.70   Shares after offering: 17.8...
BC Extra | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
Items per page:
1 - 10 of 57